Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Vilnius University Hospital, Vilnius

Mount Sinai Medical Center, New York

Italian Group for Systemic Amyloidosis, Biotechnology Research Laboratories, IRCCS Policlinico San Matteo, Internal Medicine and Medical Oncology, Pavia

Hospital Clinico San Carlos de Madrid, Servicio de Reumatologia, Madrid

Bnai Zion Medical Center, Haifa

Indiana University School of Medicine, Department of Pathology and Laboratory Medicine,, Indianapolis

Heller Institute of Medical Research, Sheba Medical Center, Tel Litwinsky

Mayo Clinic, Rochester

Marmara University Medical School Hospital, Department of Rheumatology, Uskudar, Altunizade, Istanbul

Institute of Rheumatology RAMS, Moscow

Regional Hospital No. 1, Yekaterinburg

Boston Medical Center, Renal Division, Boston

Rheumatism Foundation Hospital, Heinola

Centre Hospitalier du Mans, Service de Rhumatologie, Le Mans

Hôpital Claude Huriez, Service de médecine Interne, Clinique Médicale A, Lille

Hôpital Cochin, Centre de Recherche et d'Explorations Fonctionnelles, Paris

University Hospital Groningen, Department of Medicine, Division of Rheumatology, Groningen

Instytut Reumatologiczny, Warsaw

Okregowy Szpital Kolejowy, Zaklad Reumatologii, Wroclaw

Hospital Universitario Germans Trias I Pujol, Servicio de Reumatologia, Badalona

Hospital Clinic I Provincial de Barcelona, Jefe del Departamento de Reumatologia, Barcelona

Ciutad Sanitària y Universitària de Bellvitge, Servicio de Reumatologia, Hospitalet de Llobregat, Llobregat

Cerrehpasa Tip Fakultesi, Askaray, Istanbul, Turkey

Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul

Royal Free and University College Medical School, Department of Medicine, National Amyloidosis Centre, London

Gartnavel General Hospital, Scotland